Pankaj Pathak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1798561/publications.pdf

Version: 2024-02-01

56 papers	1,251 citations	304743 22 h-index	377865 34 g-index
57 all docs	57 docs citations	57 times ranked	2366 citing authors

#	Article	IF	Citations
1	Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro-Oncology, 2013, 15, 718-726.	1.2	101
2	Pediatric glioblastomas: A histopathological and molecular genetic study. Neuro-Oncology, 2009, 11, 274-280.	1.2	91
3	A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. Journal of Clinical Neuroscience, 2011, 18, 66-70.	1.5	59
4	Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. Neuro-Oncology, 2014, 16, 372-381.	1.2	56
5	Telomerase reverse transcriptase (TERT) â€•enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and <scp>DNA</scp> damage responses in glioblastoma. Journal of Neurochemistry, 2017, 143, 671-683.	3.9	52
6	Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. Journal of Neuro-Oncology, 2015, 121, 489-497.	2.9	49
7	Th3 Immune responses in the progression of leprosy via molecular cross-talks of TGF-Î², CTLA-4 and Cbl-b. Clinical Immunology, 2011, 141, 133-142.	3.2	47
8	Molecular profile of oligodendrogliomas in young patients. Neuro-Oncology, 2011, 13, 1099-1106.	1.2	43
9	Characterization of Molecular Genetic Alterations in GBMs Highlights a Distinctive Molecular Profile in Young Adults. Diagnostic Molecular Pathology, 2011, 20, 225-232.	2.1	43
10	C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. Journal of Neuro-Oncology, 2018, 138, 29-39.	2.9	41
11	O 6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment. Neurosurgery, 2010, 67, 1681-1691.	1.1	40
12	Limb girdle muscular dystrophy type 2A in India: A study based on semi-quantitative protein analysis, with clinical and histopathological correlation. Neurology India, 2010, 58, 549.	0.4	37
13	Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors. Carcinogenesis, 2017, 38, bgw126.	2.8	37
14	Genomeâ€•wide small noncoding <scp>RNA</scp> profiling of pediatric highâ€grade gliomas reveals deregulation of several mi<scp>RNA</scp>s, identifies downregulation of sno<scp>RNA</scp> cluster <scp>HBII</scp>â€52 and delineates <scp>H3F3A</scp> and TP53 mutantâ€specific mi<scp>RNA</scp>s and sno<scp>RNA</scp>s. International Journal of Cancer, 2015, 137, 2343-2353.	5.1	36
15	IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Experimental and Molecular Pathology, 2011, 91, 385-393.	2.1	34
16	Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro-Oncology, 2014, 16, 1607-1617.	1.2	32
17	Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genetics, 2015, 208, 91-95.	0.4	29
18	Detection of Allelic Status of 1p and 19q by Microsatellite-based PCR Versus FISH. Diagnostic Molecular Pathology, 2011, 20, 40-47.	2.1	28

#	Article	IF	Citations
19	Alterations in BRAF gene, and enhanced mTOR and MAPK signaling in dysembryoplastic neuroepithelial tumors (DNTs). Epilepsy Research, 2016, 127, 141-151.	1.6	26
20	Downregulation of SMARCB1/INI1 expression in pediatric chordomas correlates with upregulation of miR-671-5p and miR-193a-5p expressions. Brain Tumor Pathology, 2017, 34, 155-159.	1.7	26
21	Genetic alterations related to <scp>BRAFâ€FGFR</scp> genes and dysregulated <scp>MAPK/ERK</scp>/m<scp>TOR</scp> signaling in adult pilocytic astrocytoma. Brain Pathology, 2017, 27, 580-589.	4.1	26
22	TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Experimental and Molecular Pathology, 2011, 90, 167-172.	2.1	24
23	Expression of DNA methyltransferases 1 and 3B correlates with EZH2 and this 3-marker epigenetic signature predicts outcome in glioblastomas. Experimental and Molecular Pathology, 2016, 100, 312-320.	2.1	23
24	Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature. Pathology Research and Practice, 2018, 214, 679-685.	2.3	22
25	Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients. Neurology India, 2011, 59, 254.	0.4	20
26	Study of Î²-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases. Journal of Neuro-Oncology, 2017, 133, 487-495.	2.9	19
27	Epithelial-to-mesenchymal transitionâ€“related transcription factors are up-regulated in ependymomas and correlate with a poor prognosis. Human Pathology, 2018, 82, 149-157.	2.0	19
28	Clinicopathological and molecular characteristics of pediatric meningiomas. Neuropathology, 2018, 38, 22-33.	1.2	18
29	Myopathy associated LDB3 mutation causes Z-disc disassembly and protein aggregation through PKCÎ± and TSC2-mTOR downregulation. Communications Biology, 2021, 4, 355.	4.4	18
30	Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas. Journal of Neuro-Oncology, 2018, 139, 23-31.	2.9	17
31	ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. Brain Pathology, 2017, 27, 138-145.	4.1	16
32	Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescenceÂin-situ hybridization in resource constrained centres. Journal of Neuro-Oncology, 2019, 143, 393-403.	2.9	16
33	C11orf95â€RELA fusion present in a primary intracranial extraâ€axial ependymoma: Report of a case with literature review. Neuropathology, 2016, 36, 490-495.	1.2	15
34	Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors. Brain Tumor Pathology, 2016, 33, 117-128.	1.7	15
35	Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India. Translational Oncology, 2016, 9, 371-376.	3.7	11
36	mTOR pathway activation in focal cortical dysplasia. Annals of Diagnostic Pathology, 2020, 46, 151523.	1.3	10

#	Article	IF	Citations
37	Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurology India, 2009, 57, 559.	0.4	9
38	Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genetics and Cytogenetics, 2010, 198, 126-134.	1.0	9
39	miR-217â€“casein kinase-2 cross talk regulates ERK activation in ganglioglioma. Journal of Molecular Medicine, 2017, 95, 1215-1226.	3.9	8
40	A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India. Brain Tumor Pathology, 2016, 33, 183-190.	1.7	7
41	Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma â€“ A study of 28 cases. Neurology India, 2016, 64, 988.	0.4	7
42	1p/14q co-deletion: A determinant of recurrence in histologically benign meningiomas. Indian Journal of Pathology and Microbiology, 2015, 58, 433.	0.2	5
43	BRAF gene alterations and enhanced mammalian target of rapamycin signaling in gangliogliomas. Neurology India, 2017, 65, 1076.	0.4	4
44	Mutational Spectrum of CAPN3 with Genotype-Phenotype Correlations in Limb Girdle Muscular Dystrophy Type 2A/R1 (LGMD2A/LGMDR1) Patients in India. Journal of Neuromuscular Diseases, 2021, 8, 125-136.	2.6	3
45	EPN-13EPITHELIAL-TO-MESENCHYMAL TRANSITIONS IN CHILDHOOD EPENDYMOMAS MECHANISTICALLY LINKS ONCOGENIC C11orf95-RELA FUSION DRIVEN ACTIVATION OF SNAI1/SNAIL. Neuro-Oncology, 2016, 18, iii33.1-iii33.	1.2	1
46	Pediatric High Grade Glioma. Current Cancer Research, 2017, , 241-266.	0.2	1
47	Loss of SMARCB1/INI1 Immunoexpression in Chordoid Meningiomas. Neurology India, 2019, 67, 1492.	0.4	1
48	Progressive weakness in a 12-year-old boy. Journal of Clinical Neuroscience, 2011, 18, 1686.	1.5	0
49	Progressive weakness in a 12-year-old boy. Journal of Clinical Neuroscience, 2011, 18, 1751.	1.5	0
50	EPIG-08DOWNREGULATION OF miR-379/miR-656 CLUSTER (C14MC) IN OLIGODENDROGLIOMAS WITH POSSIBLE MECHANISTIC AND CLINICOPATHOLOGICAL IMPLICATIONS. Neuro-Oncology, 2015, 17, v87.4-v88.	1.2	0
51	GENO-31MOLECULAR GENETIC PROFILE OF ADULT PILOCYTIC ASTROCYTOMA: BRAF-FGFR GENOMIC ALTERATIONS AND ACTIVATION OF MAPK/ERK/mTOR PATHWAY. Neuro-Oncology, 2015, 17, v98.3-v98.	1.2	0
52	EPN-03C11orf95-RELA FUSION POSITIVE PEDIATRIC SUPRATENTORIAL EPENDYMOMAS ARE AN AGGRESSIVE SUBSET WITH INCREASED EXPRESSION OF STEM CELL MARKER NESTIN AND VASCULAR ENDOTHELIAL DERIVED GROWTH FACTOR. Neuro-Oncology, 2016, 18, iii30.3-iii31.	1.2	0
53	134 Clinicopathological and Molecular Characteristics of Pediatric Versus Adult Meningiomas. Neurosurgery, 2017, 64, 230-231.	1.1	0
54	MBRS-55. MOLECULAR CLASSIFICATION OF MEDULLOBLASTOMAS: NANOSTRING nCOUNTER ASSAY VS A COMBINATION OF IMMUNOHISTOCHEMISTRY AND FLUORESCENCE IN-SITU HYBRIDISATION. Neuro-Oncology, 2018, 20, i140-i140.	1.2	0

#	Article	IF	Citations
55	P.84Impaired cargo-selective autophagy due to altered signaling causes the Z-disc myofibrillar disintegration in myofibrillar myopathy due to LDB3-A165V mutation in a knock-in mouse model. Neuromuscular Disorders, 2019, 29, S65.	0.6	0
56	P14.117 Cost efficient test algorithm for molecular subgrouping of medulloblastomas for day-to-day practice in resource limited countries. Neuro-Oncology, 2019, 21, iii96-iii96.	1.2	0